Tg Therapeutics (TGTX) EBT Margin (2016 - 2025)
Historic EBT Margin for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 16.02%.
- Tg Therapeutics' EBT Margin rose 109300.0% to 16.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.5%, marking a year-over-year increase of 217400.0%. This contributed to the annual value of 7.78% for FY2024, which is 21900.0% up from last year.
- Tg Therapeutics' EBT Margin amounted to 16.02% in Q3 2025, which was up 109300.0% from 21.91% recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' EBT Margin ranged from a high of 68.71% in Q3 2023 and a low of 100501.25% during Q4 2022
- For the 5-year period, Tg Therapeutics' EBT Margin averaged around 9240.29%, with its median value being 296.19% (2023).
- In the last 5 years, Tg Therapeutics' EBT Margin surged by 2000000000bps in 2021 and then crashed by -964501500bps in 2022.
- Tg Therapeutics' EBT Margin (Quarter) stood at 4051.1% in 2021, then crashed by -2381bps to 100501.25% in 2022, then skyrocketed by 100bps to 31.9% in 2023, then surged by 174bps to 23.53% in 2024, then plummeted by -32bps to 16.02% in 2025.
- Its last three reported values are 16.02% in Q3 2025, 21.91% for Q2 2025, and 4.52% during Q1 2025.